The study was fully sponsored by Riemser Arzneimittel AG. J. Wohlrab was a paid investigator by Riemser Arzneimittel AG. WG Franke is an employee of Riemser Arzneimittel AG.
Clinical Trial for Safety Evaluation of Hyaluronidase as Diffusion Enhancing Adjuvant for Infiltration Analgesia of Skin with Lidocaine
Version of Record online: 7 SEP 2011
© by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.
Volume 38, Issue 1, pages 91–96, January 2012
How to Cite
Wohlrab, J., Finke, R., Franke, W. G. and Wohlrab, A. (2012), Clinical Trial for Safety Evaluation of Hyaluronidase as Diffusion Enhancing Adjuvant for Infiltration Analgesia of Skin with Lidocaine. Dermatologic Surgery, 38: 91–96. doi: 10.1111/j.1524-4725.2011.02146.x
- Issue online: 5 JAN 2012
- Version of Record online: 7 SEP 2011
Infiltration anesthesia of the skin is an analgesic procedure often practiced before minor surgical interventions or punctures. The addition of hyaluronidase is a possible option to improve the effectiveness of the local anesthetic with respect to expansion of effect.
To validate the safety of intracutaneous application of hyaluronidase as a lidocaine adjuvant.
Materials and Methods
The influence of adjuvant hyaluronidase on wound healing was investigated using the suction blister method in a prospective, single-center, placebo-controlled, double-blind, intraindividual comparison study with 20 participants. The target parameters were defined as the time of normalization of transepidermal water loss, hemovascular perfusion, and complete macroscopic epithelization of the wound.
No evidence was found that adjuvant application of hyaluronidase retards wound healing.
The addition of hyaluronidase to lidocaine in intracutaneous infiltration analgesia does not lead to retardation of wound healing, and no additional relevant risks were observed.